Current Report Filing (8-k)
March 07 2022 - 08:16AM
Edgar (US Regulatory)
0000849636 false 0000849636 2022-03-07
2022-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March 7, 2022
RESPIRERX PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
1-16467 |
|
33-0303583 |
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
|
126 Valley Road,
Suite C
Glen Rock,
New Jersey
|
|
07452 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(201)
444-4947
(Former
name or former address, if changed since last
report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure.
RespireRx
Pharmaceuticals Inc. (the “Company”) issued a press release
entitled “Letter to Stockholders and Stakeholders: A Brief Summary
of Our Progress During the Past Twelve Months and a Peek Looking
Forward.” A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated herein by
reference.
The
press release that is Exhibit 99.1 includes certain forward-looking
information.
The
information in this Item 7.01 and the press release attached as
Exhibit 99.1 is being furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities and Exchange Act of 1934,
as amended (the “Exchange Act”), nor otherwise subject to the
liabilities of that section, nor incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Date:
March 7, 2022 |
RESPIRERX PHARMACEUTICALS INC. |
|
|
(Registrant) |
|
|
|
|
|
|
By: |
/s/
Jeff E. Margolis |
|
|
|
Jeff
E. Margolis |
|
|
|
SVP,
CFO, Secretary and Treasurer |
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From May 2022 to Jun 2022
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Jun 2021 to Jun 2022
